High Glucose Levels in Cancer Patients and Their Impact

Elevated blood sugar is both common and consequential in people with cancer. A large analysis of U.S. cancer survivors found that higher HbA1c and fasting glucose levels were each independently linked to increased risk of death, with a threshold effect kicking in around an HbA1c of 5.4% and a fasting glucose of about 5.7 mmol/L.¹ The relationship runs deeper than a simple correlation on a chart, though. High glucose feeds into tumor biology, undermines treatment effectiveness, and creates side effects that chip away at quality of life.

Why Tumors Are Hungry for Glucose

Most healthy cells generate the bulk of their energy through oxygen-dependent pathways in the mitochondria. Cancer cells do something different. Even when they have perfectly functional mitochondria and plenty of oxygen, many tumors ramp up their glucose intake and ferment it into lactate, a far less efficient process from an energy standpoint.² This behavior, first described nearly a century ago, means that tumors are disproportionately reliant on glucose compared with normal tissue. The inefficiency is actually strategic: the byproducts of rapid glucose breakdown supply the building blocks that fast-dividing cells need to construct new membranes, DNA, and proteins. In practical terms, a tumor sitting in a high-glucose environment has more raw material to work with.

The Insulin and Growth Factor Connection

Blood sugar does not act on tumors in isolation. When glucose stays chronically elevated, the body produces more insulin to compensate. That excess insulin has knock-on effects beyond sugar regulation. Hyperinsulinemia boosts the production and activity of insulin-like growth factor 1 (IGF-1), and higher levels of insulin, IGF-1, and the related IGF-2 have all been tied to tumor growth in lab studies, animal models, and human epidemiological data.³ IGF-1 signaling activates a cascade of pro-growth pathways inside cells, switches on glucose transporters that pull even more sugar into the cell, and can turn up key glycolytic enzymes and oncogenes that push a cell further down the road toward malignant behavior.⁴

Lab work on breast cancer cells has added a finer point. Researchers found that IGF-1 secretion from cells is directly glucose-dependent: cells bathed in higher concentrations of glucose release more mature IGF-1 into their surroundings, and that secreted IGF-1 activates the IGF-1 receptor on nearby breast cancer cells, stimulating their growth. The effect was most pronounced at high glucose combined with low insulin concentrations, mimicking a fasting-with-hyperglycemia state.⁵ So the problem is not just that high blood sugar feeds cancer cells directly. It also amplifies a hormonal environment that encourages tumor growth from the outside in.

How Cancer Treatment Itself Raises Blood Sugar

Here is a frustrating irony: many standard cancer treatments push blood sugar up. The most common culprit is dexamethasone, a steroid used routinely to prevent nausea during chemotherapy and to reduce swelling around brain tumors. In one study of cancer patients receiving chemotherapy with dexamethasone as an antiemetic, about 58% became insulin resistant and roughly 22% developed steroid-induced diabetes within the first six months of treatment. The risk climbed with higher cumulative doses of the steroid.⁶

These glucose spikes are not always permanent, but they can be dramatic. A study of early-stage breast cancer patients without pre-existing diabetes who received dexamethasone before taxane chemotherapy found that two-thirds developed steroid-induced hyperglycemia. In over 90% of those cases it was transient, resolving after treatment ended, but the patients whose glucose topped 200 mg/dL showed the wildest swings in blood sugar during the treatment period.⁷ In glioblastoma patients, perioperative dexamethasone was consistently linked to elevated glucose, and both short-lived and persistent hyperglycemia were tied to worse functional recovery, more infections, longer hospital stays, and reduced survival.⁸

So patients who walk into treatment with normal blood sugar can develop hyperglycemia because of the treatment itself, and that new hyperglycemia may then worsen their outcomes. It is a cycle that catches many people off guard.

When High Glucose Blunts Chemotherapy

Beyond feeding tumor cells and ramping up growth signals, elevated glucose appears to make certain cancers harder to kill with standard drugs. The evidence is clearest in colorectal cancer. In patients with stage III disease receiving oxaliplatin-based chemotherapy, high blood sugar was linked to significantly worse clinical outcomes. The proposed mechanism involves glucose-driven changes in specific proteins within tumor cells that promote resistance to the drug.⁹ The researchers distinguished between having diabetes as a diagnosis and having actively elevated blood sugar at the time of treatment, and it was the glucose levels themselves, not the diabetes label, that mattered most for chemoresistance. That distinction is worth paying attention to, because it implies that even someone without a diabetes diagnosis could be at risk if their glucose is poorly controlled during treatment.

The theme extends beyond a single drug. Hyperglycemia has been described as contributing to resistance to cell death and to a generally more treatment-resistant tumor phenotype across cancer types.¹⁰ For patients undergoing radiation therapy, diabetes is recognized as an important risk factor for radiation pneumonitis, a potentially serious lung inflammation that can limit how much radiation a patient can safely receive.¹¹

Immunotherapy and Glucose Control

Immune checkpoint inhibitors have transformed treatment for many cancers, but their effectiveness may also take a hit from poor glucose control. An analysis presented at a major European oncology meeting studied patients with advanced cancer on immunotherapy and found that those with a high diabetes medication burden, a proxy for long-standing or poorly controlled diabetes, had roughly 40% shorter progression-free survival and about 44% shorter overall survival compared with patients without diabetes, after adjusting for a long list of other factors.¹² The researchers also found that higher mean blood glucose predicted a higher neutrophil-to-lymphocyte ratio, a marker of inflammation that is itself associated with worse immunotherapy outcomes. The study’s authors explicitly recommended pursuing strategies to improve glycemic control in patients about to start immunotherapy.

The mechanism likely involves how chronic hyperglycemia reshapes the immune environment around tumors. When the immune system is already stressed by metabolic dysfunction, the drugs designed to unleash it against cancer have a harder job. A recent review pulled these threads together, confirming that poor glycemic control and large swings in glucose are associated with worse outcomes across chemotherapy, targeted agents, and immunotherapy alike.¹³

Breast Cancer and Pancreatic Cancer Show Especially Strong Links

While the glucose-cancer relationship appears across many tumor types, certain cancers have been studied in more depth. In breast cancer, women with elevated random blood glucose levels before diagnosis had roughly three times the risk of death compared with women whose levels were not elevated, even after controlling for tumor grade, stage, race, and body weight.¹⁴ A separate study of over 1,200 women with invasive breast cancer found that fasting blood glucose levels in the upper ranges of the distribution were tied to significantly higher risks of recurrence, distant metastasis, and death. Those risks persisted even after accounting for body mass index, though they were somewhat attenuated.¹⁵

Pancreatic cancer has an even more tangled relationship with blood sugar. Up to 80% of pancreatic cancer patients are either hyperglycemic or diabetic, and in many cases the diabetes can be detected before the cancer itself produces symptoms.¹⁶ This is not just a coincidence of shared risk factors. The diabetes often improves after the tumor is surgically removed, suggesting that the cancer itself is causing the metabolic disruption. For older adults who develop diabetes out of the blue, the risk of harboring a hidden pancreatic tumor is roughly eight times higher than in the general population.

The clinical implications run in both directions. New-onset diabetes in pancreatic cancer patients predicts worse outcomes: survival was shorter (about 22 months versus 33 months) and early recurrence was significantly more likely compared with patients who did not have diabetes.¹⁷ The emerging understanding is that long-standing type 2 diabetes modestly raises the background risk for pancreatic cancer, while new-onset diabetes after age 50 may itself be a symptom of an already-growing tumor.¹⁸

Advanced Glycation End-Products and Metastasis

When blood sugar stays high for extended periods, glucose reacts with proteins and fats in the body to form compounds called advanced glycation end-products, often shortened to AGEs. These are not just markers of metabolic damage; they actively participate in cancer progression. In cancer cells, AGEs trigger a series of molecular events that promote the breakdown and remodeling of the tissue surrounding a tumor, making it easier for cancer cells to invade nearby structures and spread to distant sites.¹⁹ Cancer patients with diabetes tend to have higher metastasis rates and worse survival than non-diabetic cancer patients, and their long-term exposure to AGEs is one proposed explanation.

Lab experiments with lung cancer cells showed that specific AGEs promoted invasion and migration, ramped up inflammatory signaling molecules, and increased production of enzymes that degrade the structural scaffolding between cells.²⁰ The implication is that sustained hyperglycemia doesn’t just create a favorable local environment for tumor growth. Over time, it generates a systemic chemical environment that makes the spread of cancer more likely.

Targeted Cancer Drugs That Cause Hyperglycemia

Steroids are not the only cancer drugs that spike blood sugar. A newer class of targeted therapies, PI3K inhibitors, cause hyperglycemia as an inherent consequence of how they work. The PI3K pathway helps cells take up and use glucose, so blocking it to starve a tumor also disrupts glucose processing elsewhere in the body. Alpelisib, a PI3K inhibitor used in breast cancer, causes hyperglycemia in about 59% of patients who take it.²¹

Guidelines for managing this side effect are tiered. For mild fasting glucose elevations up to 160 mg/dL, metformin is started at a low dose. If levels climb to 160–250 mg/dL, the cancer drug can continue while metformin is increased and an endocrinologist may be consulted. Above 250 mg/dL, the cancer drug is typically paused for a day or two while blood sugar comes down, and insulin may be needed in severe cases.²² The concern is that unmanaged hyperglycemia can force treatment interruptions or dose reductions, potentially reducing the drug’s anticancer benefit. There is also a feedback loop to worry about: the increased insulin secretion triggered by the drug’s effect on glucose can activate insulin and IGF-1 receptors on tumor cells, providing them a survival signal that partially undermines the drug’s purpose.

The Role of Glycemic Variability

Oncologists have increasingly focused not just on whether blood sugar is high on average, but on how much it swings up and down. Glycemic variability, the roller coaster of spikes and dips that can occur throughout a treatment day, has been associated with adverse events in cancer patients independently of average glucose levels.²³ This makes intuitive sense: a patient whose glucose bounces between 80 and 300 mg/dL across the day is metabolically stressed in a way that a steady 120 mg/dL is not, even if the averages are similar.

This has practical implications for monitoring. A single fasting glucose check in the morning may miss the dexamethasone-induced spike that happens six hours after a dose. Continuous glucose monitors, the kind widely used in diabetes care, are starting to appear in oncology discussions as a way to catch these swings. The idea is still in early stages for widespread oncology use, but the rationale is straightforward: you cannot manage what you do not measure, and standard lab draws are not designed to capture the glucose volatility that cancer treatment produces.

Dietary Approaches Under Investigation

Given the evidence linking glucose to tumor biology, researchers have asked whether deliberately lowering blood sugar through diet might help. The ketogenic diet, which sharply restricts carbohydrates in favor of fats, is the most studied dietary intervention in this context. A phase 1 trial in glioblastoma patients found that a ketogenic diet was safe and feasible alongside standard treatment. All 17 patients maintained nutritional ketosis on more than half their study days, and no serious adverse events related to the diet occurred.²⁴ A separate trial in women with metastatic breast cancer on chemotherapy showed that patients could safely achieve and maintain ketosis for up to six months, with improvements in body composition and insulin resistance.²⁵

These trials were designed to test safety and feasibility, not to prove that ketogenic diets improve cancer survival. Larger randomized trials are now underway for glioblastoma. The evidence so far says it can be done safely, but not yet that it changes outcomes. The broader point is more grounded: keeping blood sugar under reasonable control during cancer treatment appears to matter for multiple reasons, and diet is one lever people can potentially use, alongside medication, to do that.

When Cancer Causes the Glucose Problem

A misconception worth addressing is that high glucose in cancer patients always traces back to pre-existing diabetes or steroid use. Sometimes the tumor itself disrupts glucose metabolism. Pancreatic cancer is the clearest example, as described earlier, but the phenomenon is not limited to the pancreas. Tumors can alter hormonal signaling, trigger systemic inflammation that worsens insulin resistance, and secrete factors that shift the body’s metabolic set point. For patients and their families, this means that new blood sugar problems during cancer treatment should not be automatically chalked up to lifestyle or steroids alone. They deserve clinical attention because they may reflect something about the tumor’s behavior and because they create a metabolic environment that can undermine treatment.

Metformin, the most commonly prescribed diabetes drug, has attracted particular interest in oncology because it lowers blood sugar through a mechanism that may also affect cancer cells. Lab studies have shown that cancer cells deprived of glucose are more vulnerable to metformin, with survival dropping sharply compared with cells in glucose-rich conditions.²⁶ Whether this translates into meaningful clinical benefit in humans is still an open question, with trials ongoing across several cancer types. But it illustrates why glucose is an active variable in cancer care, not just a number on a lab report.

Peripheral Neuropathy and Quality of Life

Beyond survival and tumor response, glucose levels may also affect the day-to-day experience of cancer treatment. Chemotherapy-induced peripheral neuropathy, the painful tingling and numbness in hands and feet that many patients dread, has been investigated as a potential consequence of treatment-related hyperglycemia. A study of breast cancer patients found that hyperglycemia was somewhat more common in patients who developed neuropathy than in those who did not, with mean glucose levels numerically higher at multiple time points, though these differences did not reach statistical significance in the small study population.²⁷ The connection is biologically plausible because high glucose damages small nerve fibers in diabetic neuropathy, and chemotherapy attacks those same fibers through different mechanisms. Whether the two insults compound each other in a clinically meaningful way awaits larger studies, but the question is being actively pursued.

The broader quality-of-life picture includes fatigue, wound healing, and infection risk. Hyperglycemia impairs immune function in well-established ways, and surgical patients with elevated blood sugar tend to have higher complication rates. For cancer patients who may already be immunosuppressed from chemotherapy, an additional metabolic hit to their immune defenses is unwelcome. None of this means a cancer patient who occasionally has a high reading is doomed. It means that glucose is one of the modifiable factors in an otherwise chaotic treatment landscape, and paying attention to it is a reasonable investment of clinical effort.